Director – Patient Advocacy
ITF Therapeutics
Director – Patient Advocacy
ITF Therapeutics
Develops and commercializes rare-disease therapies
About This Role:
The Director, Patient Advocacy, Inherited Metabolic Disorders (IMD) serves as the strategic leader responsible for shaping and advancing the U.S. patient advocacy strategy for IMD. This role will foster meaningful partnerships across the IMD community, ensuring patient and caregiver perspectives are integrated into company priorities, development programs, and business strategies. The Director will lead high-impact collaborations with advocacy organizations and drive the incorporation of community insights into cross-functional planning and decision-making across the product lifecycle. Through these efforts, the role will help strengthen trust, advance shared goals, and enhance outcomes for the IMD community.
This role will be remotely based.
What You'll Do:
Who You Are:
The right person for this role is a passionate advocate and strategic thinker who understands the unique challenges and opportunities within the rare disease community. They are highly credible with external stakeholders, skilled at fostering trust-based partnerships, and driven by a commitment to improving outcomes for individuals and families impacted by IMD.
Required Skills:
Preferred Skills:
Additional Information:
The base compensation range for this role is: $225,000 - $245,000. Base salary offered is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics